Insufficiency

Global Beauty Supplements Market Report 2022: Increasing Penetration of eCommerce Boosting Sector - ResearchAndMarkets.com

Retrieved on: 
Monday, November 7, 2022
Cosmetics, Retail, Online, Beauty, Awareness, Research, Growth, Vitamin, Skin care, CAGR, Woman, Population, Insufficiency, Mineral, US, Human body, Dental care, Capsule, 2020–2021 China–India skirmishes, Renewable energy, Dietary supplement

The "Global Beauty Supplements Market: Size, Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Beauty Supplements Market: Size, Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global beauty supplements market accounted for US$ 4,860.42 million in 2021 and is expected to reach US$ 10,999.96 million by 2030, expanding at a CAGR of 4.5% from 2022 to 2030.
  • The global beauty supplements market is segmented based on applications into skin care, hair care, nail care, dental care and others (overall health supplements).
  • Changing lifestyle, increasing consumer incomes leading to growth in consumption of supplements and other related factors are boosting worldwide sales of supplements.

Global Prosthetic Heart Valve Market Report to 2028 - Featuring Boston Scientific, Medtronic and Abbott Laboratories Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 18, 2022
Health, Medical Devices, Cardiology, People, Cardiovascular disease, Ageing, Risk, Disorder, Obesity, Carbon, Anticoagulant, Thrombosis, Degenerative disease, Brain, Structural Damage, Common carotid artery, Mechanical, Stroke, Titanium, Infection, CAGR, Semispherical drum, United Nations, Overweight, Hospital, Heart, Insufficiency, Blood, Housing, Heart failure, Artery, Stenosis, Medical device, Hydraulic machinery, Medical imaging

The Global Prosthetic Heart Valve Market size is expected to reach $13.3 billion by 2028, rising at a market growth of 10.7% CAGR during the forecast period.

Key Points: 
  • The Global Prosthetic Heart Valve Market size is expected to reach $13.3 billion by 2028, rising at a market growth of 10.7% CAGR during the forecast period.
  • An opening through which blood flows and a device that closes and opens the orifice make up artificial heart valves.
  • A circular disk is held in place by wire-like arms that protrude into the orifice in the tilting disk valve.
  • Mechanical heart valve failure occurs in various cases after the completion of an artificial heart valve transplant.

Mg OSTEOINJECT from Bone Solutions Receives 510(k) Clearance for Expanded Indications

Retrieved on: 
Wednesday, July 13, 2022
FDA, Health Technology, Health, Medical Devices, Peter DeMaria, Veterinary medicine, Magnesium, Cell proliferation, Ohio State University, Retail Solutions Inc., Orthopaedic Research Society, View, BSI, Insufficiency, MP, OH, Bone cement, FDA, AL, Phosphorus

Bone Solutions Inc. (BSI), an orthobiologics technology company located in Colleyville, Texas, announced today that it has received FDA 510(k) clearance for expanded indications for its Mg OSTEOINJECT .

Key Points: 
  • Bone Solutions Inc. (BSI), an orthobiologics technology company located in Colleyville, Texas, announced today that it has received FDA 510(k) clearance for expanded indications for its Mg OSTEOINJECT .
  • Mg OSTEOINJECT is the first drillable, adhesive, and injectable bone void filler in the U.S. to incorporate magnesium, a critical component for bone health and development.
  • The expanded indication includes use of the material as an adjunct to hardware fixation by supporting the bone fragments during the surgical procedure.
  • Mg OSTEOINJECT is a registered trademark of Bone Solutions, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220713005702/en/

Bone Solutions Launches Mg OSTEOINJECT Injectable Magnesium-Based Bone Void Filler

Retrieved on: 
Tuesday, January 25, 2022
Technology, Training, Communications, Other Science, Research, Medical Devices, Human Resources, Biotechnology, Education, Other Consumer, Professional Services, Health, Women, Seniors, Men, Family, Science, Other Manufacturing, Other Technology, Consumer, Other Communications, Manufacturing, Other Health, View, Patient, Insufficiency, Absorption, BSI, Calcium, FDA, Magnesium, Surgeon, Retail Solutions Inc., Elasticity, Regeneration, CEO, Ceramic, Phosphorus

Bone Solutions Inc. (BSI), an orthobiologics technology company located in Colleyville, Texas, announced today the immediate commercial launch of Mg OSTEOINJECT , the first injectable bone void filler in the U.S. to incorporate magnesium - a critical component for bone health and development.

Key Points: 
  • Bone Solutions Inc. (BSI), an orthobiologics technology company located in Colleyville, Texas, announced today the immediate commercial launch of Mg OSTEOINJECT , the first injectable bone void filler in the U.S. to incorporate magnesium - a critical component for bone health and development.
  • As the only magnesium-based bone repair product for insufficiency fractures, Mg OSTEOINJECT provides a surgical solution that is unlike anything currently available on the market.
  • Because of these characteristics, Mg OSTEOINJECT is resorbable and is designed to safely assimilate back into the body during the healing process as it is replaced with bone.
  • Mg OSTEOINJECT is a registered trademark of Bone Solutions, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220125005969/en/

Global Vein Ablation Device Market (2021 to 2026) - Featuring Angiodynamics, F Care Systems and Medtronic Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 20, 2021
Medical Devices, Health, Insufficiency, National, Thrombosis, Prevalence, Ageing, COVID-19, Awareness, Growth, Fear, Ministry of Social Affairs, Coronavirus, Department, Disease, National Institutes of Health, Varicose veins, Patient, UN, Economy, Population, Chronic venous insufficiency, Pharmaceutical industry, Birth control

The recent outbreak of the novel coronavirus had a negative impact on the global vein-ablation device market.

Key Points: 
  • The recent outbreak of the novel coronavirus had a negative impact on the global vein-ablation device market.
  • This led to a decline in vein ablation procedures in 2020 and consequently led to a decline in the growth of the global vein-ablation device market.
  • It states that the global burden of chronic venous disease consumes nearly 2% in 2019 which is constantly increasing.
  • The increasing prevalence of the disease is projected to lead to the growth of the global vein-ablation device market during the forecast period.

Tactile Medical to Present at the Guggenheim 2021 MedTech Disruptors Summit

Retrieved on: 
Wednesday, August 4, 2021
Vascular diseases, Lymphedema, Venous insufficiency, Chronic venous insufficiency, Chronic condition, Insufficiency, Medtech, Medicine, Branches of biology

MINNEAPOLIS, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (Tactile Medical) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today announced that management will participate in the Guggenheim 2021 MedTech Disruptors Summit, which is being held virtually from August 9th-10th.

Key Points: 
  • MINNEAPOLIS, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (Tactile Medical) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today announced that management will participate in the Guggenheim 2021 MedTech Disruptors Summit, which is being held virtually from August 9th-10th.
  • Tactile Medical is a leader in developing and marketing at-home therapy devices that treat chronic swelling conditions such as lymphedema and chronic venous insufficiency.
  • Tactile Medicals Mission is to help people suffering from chronic diseases live better and care for themselves at home.
  • Tactile Medical takes pride in the fact that our solutions help increase clinical efficacy, reduce overall healthcare costs and improve the quality of life for patients with chronic conditions.

Exocrine Pancreatic Insufficiency (EPI) Market Insights, Epidemiology and Market Forecast 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 8, 2021
Health, Pharmaceutical, Pancreas disorders, EPI, Insufficiency, Exocrine pancreatic insufficiency, Pancreas, Clinical medicine

The "Exocrine Pancreatic Insufficiency (EPI) - Market Insights, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Exocrine Pancreatic Insufficiency (EPI) - Market Insights, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • This 'Exocrine Pancreatic Insufficiency (EPI) -Market Insights, Epidemiology and Market Forecast- 2030' report delivers an in-depth understanding of the Exocrine Pancreatic Insufficiency (EPI), historical and forecasted epidemiology as well as the Exocrine Pancreatic Insufficiency (EPI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The drug chapter segment of the Exocrine Pancreatic Insufficiency (EPI) report encloses the detailed analysis of Exocrine Pancreatic Insufficiency (EPI) marketed drugs and mid and late stage pipeline drugs.
  • The Exocrine Pancreatic Insufficiency (EPI) market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Exocrine Pancreatic Insufficiency (EPI) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

Exocrine Pancreatic Insufficiency (EPI) Epidemiology Forecast Report 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 5, 2021
Health, Other Health, Pancreas disorders, Medical specialties, Insufficiency, EPI, Exocrine pancreatic insufficiency, Pancreas

The "Exocrine Pancreatic Insufficiency (EPI) - Epidemiology Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Exocrine Pancreatic Insufficiency (EPI) - Epidemiology Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalence of Causative Indications of EPI and Prevalence of Exocrine Pancreatic Insufficiency scenario of Exocrine Pancreatic Insufficiency (EPI) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.
  • The report covers the descriptive overview of Exocrine Pancreatic Insufficiency (EPI), explaining its causes, signs and symptoms, pathophysiology.
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Exocrine Pancreatic Insufficiency (EPI) during the forecast period (2020-2030)?

Antares Pharma Announces Submission of IND Application for ATRS-1902 for Adrenal Crisis Rescue

Retrieved on: 
Tuesday, June 22, 2021
Adrenal gland disorders, Organ systems, Drugs, Adrenal crisis, Adrenal insufficiency, Adrenal gland, Hydrocortisone, Insufficiency, Organs anatomy)

The IND application for ATRS-1902, and its corresponding development program, supports a proposed indication for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using a novel proprietary auto-injector platform to deliver hydrocortisone.

Key Points: 
  • The IND application for ATRS-1902, and its corresponding development program, supports a proposed indication for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using a novel proprietary auto-injector platform to deliver hydrocortisone.
  • Secondary adrenal insufficiency is more common, affecting approximately 150 to 280 people per million(2)(3), commented Dr. Peter Richardson, EVP, Research and Development and Chief Medical Officer of Antares Pharma.
  • Robert F. Apple, President and Chief Executive Officer of Antares Pharma, commented, This IND submission represents a key milestone for Antares as we continue to advance our proprietary pipeline.
  • The FDA will review our IND application and determine the acceptability of the submission before Antares can commence the proposed phase 1 trial for ATRS-1902.

AzurRx BioPharma Announces Positive Interim Data in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

Retrieved on: 
Thursday, May 13, 2021
Pancreas disorders, Medical specialties, Organ systems, Clinical medicine, Exocrine pancreatic insufficiency, Chronic pancreatitis, Pancreatitis, Cystic fibrosis, Insufficiency

We expect to report full topline results from all 20 patients enrolled in the trial in the second quarter of 2021.\xe2\x80\x9d\nDr.

Key Points: 
  • We expect to report full topline results from all 20 patients enrolled in the trial in the second quarter of 2021.\xe2\x80\x9d\nDr.
  • Based on the clinical evidence from the combination trial to-date, we have been able to improve the nutritional status of the severe EPI patients who need the most help.
  • It turns out that the patients with the lowest baseline CFAs had the largest improvements in CFA in the study.
  • The lead therapeutic candidate is\xc2\xa0MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis,\xc2\xa0currently in two Phase 2 clinical trials.